<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00750100</url>
  </required_header>
  <id_info>
    <org_study_id>EC REF 2006-157</org_study_id>
    <nct_id>NCT00750100</nct_id>
  </id_info>
  <brief_title>Low Dose hCG in the Late Follicular Phase</brief_title>
  <official_title>Among ICSI Patients Undergoing Antagonist Protocols With Recombinant FSH, Does Replacement of Recombinant FSH by 200 IU of hCG in the Late Follicular Phase Compared With Continuing Recombinant FSH, Result in a Similar Number of Oocytes?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitair Ziekenhuis Brussel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitair Ziekenhuis Brussel</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study,the investigators compared two protocols for controlled ovarian
      hyperstimulation in infertility patients requiring IVF. In the control group, the patient
      undergoes a standard antagonist protocol. In the study group, the administration of
      gonadotropins is stopped in the late follicular phase and replaced by low dose human
      chorionic gonadotropins. The primary endpoint of the study is the number of oocytes retrieved
      in both groups.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of oocytes in both treatment groups</measure>
    <time_frame>up to 9 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of stimulation in both treatment groups, amount of gonadotropins consumed in each treatment group</measure>
    <time_frame>up to 9 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients undergo a standard antagonist protocol for in-vitro fertilisation, and are stimulated with recombinant gonadotropins.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients are undergo an antagonist protocol for in-vitro fertilisation and are stimulated with recombinant gonadotropins. When the patient has an estradiol value of 600 ng/L or more and when the patient has at least 6 follicles of 12 mm, the administration of gonadotropins is stopped and replaced by low dose human chorionic gonadotropins.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>human chorionic gonadotropin</intervention_name>
    <description>hCG 200IU in the late follicular phase</description>
    <arm_group_label>B</arm_group_label>
    <other_name>Pregnyl, NV Organon, Oss, The Netherlands</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>recombinant gonadotropins</intervention_name>
    <description>200 IU per day during controlled ovarian stimulation</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Puregon, NV Organon, Oss, The Netherlands</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  &lt; 36 years on day of randomisation

          -  FSH &lt; 12 in the early follicular phase

          -  Normal ultrasound scan

          -  BMI between 18 and 29 (both inclusive)

          -  Randomisation at outpatient clinic

        Exclusion Criteria:

          -  Endometriosis â‰¥ grade 3

          -  PCO syndrome

          -  Poor responder

          -  Endocrine or metabolic abnormalities
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>36 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christophe Blockeel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UZ Brussel, Centre for Reproductive Medicine, Brussels</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UZ Brussel</name>
      <address>
        <city>Laarbeeklaan 101</city>
        <state>Brussels</state>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <reference>
    <citation>Filicori M, Cognigni GE, Gamberini E, Parmegiani L, Troilo E, Roset B. Efficacy of low-dose human chorionic gonadotropin alone to complete controlled ovarian stimulation. Fertil Steril. 2005 Aug;84(2):394-401.</citation>
    <PMID>16084880</PMID>
  </reference>
  <verification_date>September 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 9, 2008</study_first_submitted>
  <study_first_submitted_qc>September 9, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 10, 2008</study_first_posted>
  <last_update_submitted>October 8, 2010</last_update_submitted>
  <last_update_submitted_qc>October 8, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 11, 2010</last_update_posted>
  <responsible_party>
    <name_title>Paul Devroey</name_title>
    <organization>Universitair Ziekenhuis Brussel</organization>
  </responsible_party>
  <keyword>infertility</keyword>
  <keyword>IVF</keyword>
  <keyword>hCG</keyword>
  <keyword>primary infertility</keyword>
  <keyword>secondary infertility</keyword>
  <keyword>patients requiring in-vitro fertilisation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chorionic Gonadotropin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

